Walleye Trading
ALXN

Walleye Trading’s Alexion Pharmaceuticals ALXN Stock Holding History

Walleye Trading’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,800
Closed -$3.09M – 6110
2021
Q2 		$3.09M Buy
16,800
+8,100
+93% +$1.39M 0.01% 1145
2021
Q1 		$1.33M Sell
8,700
-16,000
-65% -$2.47M 0.01% 1673
2020
Q4 		$3.86M Buy
24,700
+7,300
+42% +$938K 0.02% 898
2020
Q3 		$1.99M Sell
17,400
-2,000
-10% -$216K 0.01% 1126
2020
Q2 		$2.18M Sell
19,400
-52,600
-73% -$5.58M 0.01% 1031
2020
Q1 		$6.46M Buy
72,000
+15,400
+27% +$1.51M 0.05% 307
2019
Q4 		$6.12M Buy
56,600
+41,000
+263% +$4.39M 0.04% 472
2019
Q3 		$1.53M Buy
15,600
+900
+6% +$101K 0.01% 1268
2019
Q2 		$1.93M Sell
14,700
-16,500
-53% -$2.13M 0.02% 1078
2019
Q1 		$4.22M Buy
31,200
+9,200
+42% +$1.14M 0.03% 587
2018
Q4 		$2.14M Buy
22,000
+17,200
+358% +$2.03M 0.02% 1022
2018
Q3 		$667K Sell
4,800
-1,400
-23% -$176K ﹤0.01% 2554
2018
Q2 		$770K Sell
6,200
-10,400
-63% -$1.22M ﹤0.01% 2383
2018
Q1 		$1.85M Buy
16,600
+14,400
+655% +$1.72M 0.01% 1273
2017
Q4 		$263K Sell
2,200
-32,000
-94% -$3.9M ﹤0.01% 3206
2017
Q3 		$4.8M Sell
34,200
-800
-2% -$109K 0.02% 690
2017
Q2 		$4.26M Buy
35,000
+24,300
+227% +$2.83M 0.03% 681
2017
Q1 		$1.3M Buy
+10,700
New +$1.38M 0.01% 1423
2016
Q4 		– Sell
-800
Closed -$98K – 5371
2016
Q3 		$98K Sell
800
-15,100
-95% -$1.94M ﹤0.01% 3308
2016
Q2 		$1.86M Sell
15,900
-200
-1% -$28.4K 0.01% 1049
2016
Q1 		$2.24M Sell
16,100
-19,290
-55% -$2.83M 0.02% 780
2015
Q4 		$6.75M Buy
35,390
+33,700
+1,994% +$5.89M 0.07% 290
2015
Q3 		$265K Sell
1,690
-1,610
-49% -$294K ﹤0.01% 2100
2015
Q2 		$597K Buy
3,300
+2,900
+725% +$500K 0.01% 1516
2015
Q1 		$69K Sell
400
-13,800
-97% -$2.5M ﹤0.01% 2904
2014
Q4 		$2.63M Buy
14,200
+14,000
+7,000% +$2.59M 0.02% 561
2014
Q3 		$34K Sell
200
-1,300
-87% -$213K ﹤0.01% 3345
2014
Q2 		$236K Buy
+1,500
New +$237K ﹤0.01% 1871
2014
Q1 		– Sell
-400
Closed -$53K – 4043
2013
Q4 		$53K Buy
+400
New +$48K ﹤0.01% 2806

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Walleye Trading's ALXN Position: Q3 2021 in Review

Walleye Trading sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 18,742 shares — an estimated $3.44M sold.

Walleye Trading first reported a position in ALXN in Q3 2013 and held it in 24 quarters. The position peaked at $5.37M in Q1 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Walleye Trading reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Walleye Trading sold 18,742 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.44M.
  • Walleye Trading first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 24 quarters.
  • Walleye Trading's Alexion Pharmaceuticals position peaked at $5.37M in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Walleye Trading's 13F filing for Q3 2021, filed 15 Nov 2021.